Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
ConclusionDifferent drug properties previously linked to the occurrence of DILI may partially explain the reporting pattern observed with UPA. Our “bedside-to-bench” approach may support regulators in the risk–benefit assessment of UPA.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | European Medicines Agency (EMA) | Hepatitis | Liver | Statistics | Urology & Nephrology